Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

Background: Rituximab (RTX) is a monoclonal antibody that selectively targets CD20 and is frequently used in the treatment of membranous nephropathy (MN). Analysis of the therapeutic efficacy and safety of RTX in treating MN in practice and a comparative pharmacoeconomic analysis of the RTX and trad...

Full description

Bibliographic Details
Main Authors:	Li Zeng, Huihui Chen, Heng Xiang, Mengru Zeng, Mi Zhou, Chongqing Tan, Hong Liu, Guochun Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Pharmacology
Subjects:	Markov model membranous nephropathy pharmacoeconomic analysis rituximab tacrolimus
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1309930/full

Similar Items

Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy
by: Hui-Lin Xing, et al.
Published: (2024-02-01)

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
by: Liu Y, et al.
Published: (2023-05-01)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
by: Maxime Teisseyre, et al.
Published: (2021-10-01)

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
by: Liang S, et al.
Published: (2023-04-01)

Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
by: Majda Sahman, et al.
Published: (2021-03-01)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
by: Shun-Lai Shang, et al.
Published: (2018-07-01)

Efficacy and safety of rituximab in elderly patients with membranous nephropathy
by: Yanhong Guo, et al.
Published: (2023-12-01)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
by: W. Cui, et al.

Efficacy and safety of two dose regimens of rituximab for idiopathic membranous nephropathy
by: Zhi-hui Tu, et al.
Published: (2024-02-01)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
by: Hongzhen Zhong, et al.
Published: (2020-10-01)

Two cases of idiopathic membranous nephropathy treated with rituximab
by: Jae Young Yoon, et al.
Published: (2013-09-01)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
by: Shasha Chen, et al.
Published: (2020-02-01)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
by: Ping Chen, et al.
Published: (2023-02-01)

Therapeutic advances of rituximab alone or plus other drugs for membranous nephropathy
by: Chao Zhang, et al.
Published: (2024-01-01)

Case series of low dose rituximab for membranous nephropathy; a single centre experience
by: Gerry George Mathew, et al.
Published: (2023-06-01)

Clinical analysis of rituximab for adult refractory primary membranous nephropathy
by: FENG Linhong, et al.
Published: (2023-03-01)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
by: Xiao-Pei Wang, et al.
Published: (2016-01-01)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
by: Lijuan Zhao, et al.
Published: (2023-05-01)

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy
by: Lina Shao, et al.
Published: (2019-10-01)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
by: Sonia Boyer-Suavet, et al.
Published: (2020-01-01)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
by: Cheng Xue, et al.
Published: (2023-09-01)

Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life
by: Li Wang, et al.
Published: (2022-01-01)

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study
by: Carla Sans-Pola, et al.
Published: (2021-10-01)

Co-occurrence of IgA nephropathy and IgG4-Tubulointersitial nephritis effectively treated with tacrolimus: a case report
by: Mi Tian, et al.
Published: (2021-08-01)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
by: Lin W, et al.
Published: (2019-07-01)

Discussion on machine learning technology to predict tacrolimus blood concentration in patients with nephrotic syndrome and membranous nephropathy in real-world settings
by: Weijia Yuan, et al.
Published: (2022-12-01)

Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori
by: A. M. Veliyev, et al.
Published: (2019-05-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Rituximab in patients with membranous nephropathy and kidney insufficiency
by: Yanhong Guo, et al.
Published: (2022-10-01)

Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy
by: Chen Ruo-ji, et al.
Published: (2022-11-01)

Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy
by: Chen Ruo-ji, et al.
Published: (2022-11-01)

Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts
by: Mohammad-Reza Tamadon, et al.
Published: (2018-01-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
by: Raja Ramachandran, et al.
Published: (2017-07-01)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
by: Zhang C, et al.
Published: (2020-04-01)

Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study
by: Lingzhi Wu, et al.
Published: (2021-01-01)

Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study
by: Ming Xia, et al.
Published: (2020-10-01)

Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
by: Shasha Zhang, et al.
Published: (2023-04-01)

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
by: Hao Liang, et al.
Published: (2024-03-01)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
by: Shuang Gao, et al.
Published: (2021-05-01)